Company news
Lantheus Holdings, Inc. (NASDAQ:LNTH) news
Lantheus Holdings, Inc. news releases on 6ix. Latest, Sep 30, 2026: Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu…
Press releases & updates
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
September 30, 2026
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
September 29, 2026
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
September 28, 2026
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
September 22, 2026
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
August 14, 2026
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
August 7, 2026
Lantheus Reports Second Quarter 2026 Financial Results
August 6, 2026
Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
July 23, 2026
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
June 26, 2026
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
June 1, 2026
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
May 27, 2026
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
May 21, 2026
Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2026
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
April 23, 2026
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
March 16, 2026
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
March 5, 2026
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
March 2, 2026
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Lantheus to Present at March 2026 Investor Conferences
February 24, 2026
Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
February 12, 2026
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
January 1, 2026
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
November 23, 2025
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Lantheus Announces Leadership Transition Plan
November 5, 2025
Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
October 29, 2025
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
October 27, 2025
Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
October 22, 2025
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
September 23, 2025
Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 1, 2025
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
August 5, 2025
Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time
July 22, 2025
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
July 21, 2025
Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
June 10, 2025
Lantheus to Present at the 2025 Truist Securities MedTech Conference
June 9, 2025
Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
June 2, 2025
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
June 2, 2025
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
Lantheus Announces Sale of SPECT Business to SHINE Technologies
May 5, 2025
Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
April 29, 2025
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time
April 22, 2025
Lantheus Completes Acquisition of Evergreen Theragnostics
March 31, 2025
Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance
February 25, 2025
Lantheus to Present at Upcoming Investor Conferences
February 20, 2025
Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
February 11, 2025
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
February 4, 2025
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
January 29, 2025
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
January 27, 2025